In India, there are not enough healthcare professionals to meet the needs of the 65 million people with diabetes. Partnerships can change this. [photo: Jesper Westley for the World Diabetes Foundation]

Today, Novo Nordisk published its sixth business case demonstrating the shared value the company creates through its business activities. The latest Blueprint for Change case study, Developing partnerships to change diabetes in India, shows that Novo Nordisk’s partnership approach in India is benefiting the healthcare system and helping to meet the treatment needs of people with diabetes.

The case study also explores how successful efforts can be scaled even further across all India’s states and union territories.

Download Developing partnerships to change diabetes in India.

“We know what is working and who we need to work with to strengthen the healthcare system’s ability to treat the millions of people in India with diabetes,” says Charlotte Ersbøll, corporate vice president, Corporate Stakeholder Engagement, Novo Nordisk. “With the Blueprint for Change India case, we hope that we can take this knowledge and bring it to scale across India.”

Public-private partnerships changing the scenario

The number of people living with diabetes in India is expected to reach 109 million by 2035, close to double the number with diabetes today.[1] The Blueprint for Change case from India shows that the public healthcare system in India plays an essential role to adequately diagnose and treat many of the 65 million living with diabetes.

Improving the quality and accessibility of public healthcare will benefit patient health and wellbeing, and reduce the costs of complications from poorly treated diabetes. The Blueprint for Change case study measures the value of public-private partnerships in addressing the gap. One example is the Novo Nordisk’s Changing Diabetes® Barometer programme, a public-private partnership between state governments, Steno Diabetes Center and Novo Nordisk.

“With the Changing Diabetes® Barometer programme, we are bringing what we have learned in the private sector to the public sector,” says Melvin Oscar D’souza, general manager, Novo Nordisk India. “The programme takes a holistic approach to diabetes care that goes beyond products, which includes raising awareness of diabetes, building healthcare professionals’ capabilities and educating patients.”

The study shows that the Changing Diabetes® Barometer programme has proved to have high impact on breaking down the barriers to better diabetes care. Today seven states in India have committed to use the Barometer. The company aims to roll out the success to even more states over the coming years, helping people with diabetes live healthy lives and adding value to Novo Nordisk’s business.

Download the Blueprint for Change case study – Developing partnerships to change diabetes in India.

About the Blueprint for Change Progamme
The Blueprint for Change programme aspires to set new standards for measuring and optimising the impact of Novo Nordisk’s sustainability-driven activities by enhancing understanding of how Novo Nordisk creates value through its Triple Bottom Line business principle.

Through a series of case studies, Novo Nordisk provides insight into current and emerging sustainable business approaches, as well as best practices for creating shared value. The intent of the Blueprint for Change programme is not to present a perfect answer, but to present a work in progress that invites stakeholders to share their own views and together co-innovate sustainable solutions to complex societal issues.

Read more about Novo Nordisk’s Blueprint for Change Programme.

[1] International Diabetes Federation. IDF Diabetes Atlas. 6th edn. Brussels, Belgium: International Diabetes Federation, 2013.

Novo Nordisk

Novo Nordisk

Novo Nordisk is a global healthcare company with more than 90 years of innovation and leadership in diabetes care. The company also has leading positions within haemophilia care, growth hormone therapy and hormone replacement therapy. We believe that a healthy economy, environment and society are fundamental to long-term value creation. This is why we manage our business in accordance with the Triple Bottom Line business principle and consider the financial, environmental and social impact of our business decisions. The strategic commitment to corporate sustainability has brought the company onto centre stage as a leading player in today's business environment, recognised for its integrated reporting, stakeholder engagement and consistently high sustainability performance.

More from Novo Nordisk